Misplaced Pages

Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company.

A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013. In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.

References

1. "Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab" (PDF). American Medical Association.
2. "BAFF Antibody: Tabalumab, LY2127399". Lilly USA, LLC. Archived from the original on 12 August 2013.
3. "Press Release Archive - Press Release Archives".
4. "Lilly Halts Tabalumab Development for Lupus". 2 October 2014.

Now dropped by Lilly due to lack of efficacy.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Drugs developed by Eli Lilly and Company
• Monoclonal antibody stubs
• Antineoplastic and immunomodulating drug stubs